In the Netherlands, Royal DSM is reportedly considering a bid for DuPont’s nutrition and bioscience unit.
The business could fetch as much as $25 billion, according to Bloomberg, citing people familiar with the matter. They also report that DuPont is inviting bids from Kerry Group Plc and Givaudan. DuPont hopes a transaction will be announced by year-end.
Bloomberg also reports that the news sent DSM shares down over 3%.
The nutrition and bioscience unit includes DuPont’s acquisitions of Genencor International and Danisco.
Kerry has activities in dairy and would benefit from the addition of DuPont’s bacteria cultures, while Givaudan has already been building its plant-based flavorings portfolio via acquisition.